Keyphrases
Netherlands
100%
Cost-effectiveness
100%
Newborn Screening
100%
Spinal muscular Atrophy
100%
Early Treatment
22%
Early Detection
11%
Most Common Form
11%
Expert Opinion
11%
Birth Cohort
11%
Health-related Quality of Life
11%
Health Outcomes
11%
Quality-adjusted Life Years
11%
Cost-utility
11%
Health Impact
11%
Health Care Costs
11%
Health Effects
11%
Health Costs
11%
Model Validation
11%
Treatment Pathways
11%
Severe Disease
11%
Clinical Diagnosis
11%
Life-years Gained
11%
Utility Model
11%
Healthcare Resource Utilization
11%
Early Identification
11%
Age-appropriate
11%
Diagnostic Interventions
11%
Validity of Results
11%
Rare Genetic Disease
11%
Subsequent Therapy
11%
Motor Milestones
11%
Muscle Paralysis
11%
Symptom Onset
11%
Local Data
11%
Model Robustness
11%
Screening Diagnosis
11%
Cost-effective Use of Resources
11%
Progressive Weakness
11%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Spinal Muscular Atrophy
100%
Newborn Screening
100%
Health Care Cost
44%
Screening
22%
Diagnosis
11%
Quality of Life
11%
Quality Adjusted Life Year
11%
Health Outcomes
11%
Lifespan
11%
Symptomatic Treatment
11%
Paralysis
11%
Muscle Weakness
11%
Genetic Disorder
11%
Identified Patient
11%
Pharmacology, Toxicology and Pharmaceutical Science
Spinal Muscular Atrophy
100%
Paralysis
12%
Muscle Weakness
12%
Genetic Disorder
12%